Peer-Reviewed Publication
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
07 Jun 2025
In this study, we reported rates of clinically relevant biomarkers findings from over 20,000 solid tumor specimens analyzed with our flagship comprehensive genomic and immune profiling assay OmniSeq INSIGHT. Findings highlight that a multi-modal approach combining DNA sequencing, RNA sequencing, RNA immune gene expression, and immunohistochemistry results in maximal biomarker detection with a high rate of test success while optimizing tissue usage.
- Michelle F. Green
- Zachary D. Wallen
- Heidi C. Ko
- Kyle C. Strickland
- Alicia Dillard
- Jeffrey M. Conroy
- Durga Prasad Dash
- Mary K. Nesline
- Paul DePietro
- Shengle Zhang
- Kamal S. Saini
- Pratheesh Sathyan
- Marcia Eisenberg
- Brian Caveney
- Shakti Ramkissoon
- Eric A. Severson
- Rebecca A. Previs